Boston Scientific tests make-or-break support after steep decline

Boston Scientific Corporation (BSX), a leading medical device manufacturer specializing in interventional medical solutions, finds itself at a technical inflection point that could determine where the stock is heading next. After a brutal decline from the $110 zone, BSX is now testing support levels that haven’t been relevant in over a year.

The chart tells a story of momentum unwinding. BSX spent much of 2024 and early 2025 in a steady uptrend, methodically grinding higher as the medical device sector attracted institutional flows. That changed abruptly in recent weeks, with sellers overwhelming the tape and driving price down nearly 33% from the peak. What strikes me about this decline is its velocity—this wasn’t a gradual fade but rather a sharp repudiation of the prior rally.

Price currently hovers just above Support Level #1 at $71.88, a zone that provided a reliable floor during the May 2024 consolidation period. This level I’ve marked on the chart matters because it represents where buyers previously stepped in with conviction. The market has memory, and these historical turning points often become battlegrounds when revisited. If BSX can hold here and build a base, we could see a relief bounce back toward the $80-85 range as short-term sellers cover and dip buyers emerge.

However, the bearish scenario remains very much in play. Should $71.88 fail to hold, the next meaningful support sits at $69.04—my Support Level #2, marking another historical consolidation zone. A breakdown through both levels would likely trigger another wave of technical selling and potentially trap late bulls who bought the initial bounce.

For traders eyeing long positions, waiting for stabilization above $72 with a tight stop below $70 offers a defined-risk entry. Conversely, bears watching for continuation would look for a daily close beneath $71.50 to confirm weakness. The volume surge on the recent decline suggests institutional distribution, making any recovery attempt face significant overhead supply.

What happens at these support levels over the coming sessions will likely set the tone for Q1 2026 for Boston Scientific.